Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First Switch Patients

Nicholaos C Bellos, MD

Status: Completed

Conditions: Drug-induced Hypotension

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02626923

759-TBC

Details and patient eligibility

About

Hypotension does not occur with Maraviroc at a dose of 600 mg/day

Full description

A qualitative description of orthostatic hypotension in patients receiving once daily Maraviroc at 600 mg with Epzicom measured by a validated questionnaire

Enrollment: 51 patients

Sex: All

Ages: 21 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Epzicom Maraviroc once daily dosing

Exclusion criteria

• Maraviroc with any other back bone

Trial design

51 participants in 1 patient group

Patients on once daily Maraviroc

Description:

Maraviroc tablet 600 mg once daily 48 weeks